breast cancer
Conditions
Interventions
primary endocrine therapy-resistant group:None
treatment-sensitive group:None
Sponsors
The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital)
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed invasive breast cancer by needle biopsy; 2. Female, aged >=18 years; 3. Postmenopausal; 4. Performance status: ECOG score of 0-2; 5. Estrogen receptor (ER) positive; 6. Human epidermal growth factor receptor 2 (HER-2) negative; 7. Clinical stage II or III.
Exclusion criteria
Exclusion criteria: 1. Currently using other investigational drugs; 2. Inflammatory breast cancer; 3. Underwent breast cancer excisional biopsy; 4. Underwent axillary staging surgery before the start of the study; 5. Received any type of hormone replacement therapy within 4 weeks prior to the start of the study, such as megestrol acetate or raloxifene, etc.; 6. Clinical or radiological evidence of metastatic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| measurable tumor lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor drug resistance biomarkers (including genes, proteins, etc.); | — |
Countries
China
Contacts
Public ContactLi Yize
The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital)
Outcome results
None listed